Gene and Cell Therapy Group
Our research focuses on:
- vector technology and gene supplementation strategies for retinal degeneration
- development of retinal cell and stem cell transplantation techniques
- retinal phenotyping to better characterise the physical changes to the retina associated with different inherited conditions
- increasing our understanding of the underlying mechanisms of diseases that cause severe sight loss.
In the last few years, our work has led to the development of a number of clinical trials including the world’s first gene therapy trial for inherited retinal disease (LCA2) and Europe's first trial of stem cell-based therapy to repair macular damage in people with Stargardt disease. In collaboration with our various research partners both in the UK and around the world, our research aims to bring more gene and stem cell based therapies to the clinic within the coming years to treat patients with a range of sight loss conditions.